107 related articles for article (PubMed ID: 22526370)
1. B cell-activating factor: its clinical significance in multiple myeloma patients.
Fragioudaki M; Boula A; Tsirakis G; Psarakis F; Spanoudakis M; Papadakis IS; Pappa CA; Alexandrakis MG
Ann Hematol; 2012 Sep; 91(9):1413-8. PubMed ID: 22526370
[TBL] [Abstract][Full Text] [Related]
2. Serum BAFF levels are related to angiogenesis and prognosis in patients with multiple myeloma.
Fragioudaki M; Tsirakis G; Pappa CA; Aristeidou I; Tsioutis C; Alegakis A; Kyriakou DS; Stathopoulos EN; Alexandrakis MG
Leuk Res; 2012 Aug; 36(8):1004-8. PubMed ID: 22498341
[TBL] [Abstract][Full Text] [Related]
3. Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: correlation with markers of disease activity.
Alexandrakis MG; Passam FH; Sfiridaki A; Kandidaki E; Roussou P; Kyriakou DS
Am J Hematol; 2003 Apr; 72(4):229-33. PubMed ID: 12666132
[TBL] [Abstract][Full Text] [Related]
4. Serum BAFF predicts prognosis better than APRIL in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP chemotherapy.
Kim SJ; Lee SJ; Choi IY; Park Y; Choi CW; Kim IS; Yu W; Hwang HS; Kim BS
Eur J Haematol; 2008 Sep; 81(3):177-84. PubMed ID: 18510703
[TBL] [Abstract][Full Text] [Related]
5. Serum levels of angiopoietin-2 are associated with the growth of multiple myeloma.
Pappa CA; Tsirakis G; Samiotakis P; Tsigaridaki M; Alegakis A; Goulidaki N; Alexandrakis MG
Cancer Invest; 2013 Jul; 31(6):385-9. PubMed ID: 23758184
[TBL] [Abstract][Full Text] [Related]
6. Serum calcium is an independent prognostic factor of overall survival in Mexican patients with multiple myeloma.
Maillet D; Montiel-Cervantes L; Padilla-González Y; Sánchez-Cortés E; Xolotl-Castillo M; Vela-Ojed J; Reyes-Maldonado E
Rev Invest Clin; 2012; 64(1):17-24. PubMed ID: 22690525
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of TNF superfamily molecules in multiple myeloma patients: correlation with biological and clinical features.
Lemancewicz D; Bolkun L; Jablonska E; Kulczynska A; Bolkun-Skornicka U; Kloczko J; Dzieciol J
Leuk Res; 2013 Sep; 37(9):1089-93. PubMed ID: 23768867
[TBL] [Abstract][Full Text] [Related]
8. [The significance of lactate dehydrogenase and beta 2-microglobulin levels for the assessment of the prognosis and choice of therapy in multiple myeloma].
Iakovleva SV; Andreeva NE; Izgorodin AS
Ter Arkh; 1995; 67(7):35-9. PubMed ID: 7482303
[TBL] [Abstract][Full Text] [Related]
9. Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease.
Kyrtsonis MC; Vassilakopoulos TP; Siakantaris MP; Kokoris SI; Gribabis DA; Dimopoulou MN; Angelopoulou MK; Pangalis GA
Eur J Haematol; 2004 Apr; 72(4):252-8. PubMed ID: 15089762
[TBL] [Abstract][Full Text] [Related]
10. Time to first disease progression, but not beta2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy.
Palumbo A; Bringhen S; Falco P; Cavallo F; Ambrosini MT; Avonto I; Gay F; Caravita T; Bruno B; Boccadoro M
Cancer; 2007 Aug; 110(4):824-9. PubMed ID: 17594696
[TBL] [Abstract][Full Text] [Related]
11. Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma.
Gertz MA; Lacy MQ; Inwards DJ; Chen MG; Pineda AA; Gastineau DA; Greipp PR; Lust JA; Tefferi A; Witzig TE; Kyle RA; Litzow MR
Bone Marrow Transplant; 1999 Feb; 23(3):221-6. PubMed ID: 10084252
[TBL] [Abstract][Full Text] [Related]
12. Elevated B cell-activating factor of the tumour necrosis factor family in coeliac disease.
Fabris M; Visentini D; De Re V; Picierno A; Maieron R; Cannizzaro R; Villalta D; Curcio F; De Vita S; Tonutti E
Scand J Gastroenterol; 2007 Dec; 42(12):1434-9. PubMed ID: 17852877
[TBL] [Abstract][Full Text] [Related]
13. Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies.
Krystufková O; Vallerskog T; Helmers SB; Mann H; Putová I; Belácek J; Malmström V; Trollmo C; Vencovsky J; Lundberg IE
Ann Rheum Dis; 2009 Jun; 68(6):836-43. PubMed ID: 18628284
[TBL] [Abstract][Full Text] [Related]
14. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M
Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933
[TBL] [Abstract][Full Text] [Related]
15. [Prognostic importance of beta-2-microglobulin in multiple myeloma].
Avilés A; Zepeda G; Guzmán R; Talavera A; García EL; Díaz-Maqueo JC
Rev Invest Clin; 1992; 44(2):215-20. PubMed ID: 1439309
[TBL] [Abstract][Full Text] [Related]
16. [Expression and clinical significance of beta-catenin in multiple myeloma].
Li J; Zhang DB; Luo SK; Zhao Y; Huang BH; Gu JL
Ai Zheng; 2007 Sep; 26(9):1010-4. PubMed ID: 17927863
[TBL] [Abstract][Full Text] [Related]
17. High serum level of endostatin in multiple myeloma at diagnosis but not in the plateau phase after treatment.
Urbańska-Ryś H; Robak T
Mediators Inflamm; 2003 Aug; 12(4):229-35. PubMed ID: 14514474
[TBL] [Abstract][Full Text] [Related]
18. BAFF and BAFF-R of peripheral blood and spleen mononuclear cells in idiopathic thrombocytopenic purpura.
Zhou Z; Chen Z; Li H; Chen X; Xu J; Gu D; Du W; Zheng C; Zhang L; Huang Y; Ren Q; Yang R
Autoimmunity; 2009 Feb; 42(2):112-9. PubMed ID: 19005881
[TBL] [Abstract][Full Text] [Related]
19. Serum proinflammatory mediators at different periods of therapy in patients with multiple myeloma.
Kuku I; Bayraktar MR; Kaya E; Erkurt MA; Bayraktar N; Cikim K; Aydogdu I
Mediators Inflamm; 2005 Aug; 2005(3):171-4. PubMed ID: 16106104
[TBL] [Abstract][Full Text] [Related]
20. The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma.
Hatjiharissi E; Terpos E; Papaioannou M; Hatjileontis C; Kaloutsi V; Galaktidou G; Gerotziafas G; Christakis J; Zervas K
Hematol Oncol; 2004 Dec; 22(4):159-68. PubMed ID: 15991268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
